The White House has pulled the nomination of Dr. Heidi Overton to be commissioner of the Food and Drug Administration, on the eve of a crucial vote on her confirmation by a Senate panel, according to two people familiar with the decision.
Dr. Overton, a White House domestic policy adviser who has been involved in developing some of the administration’s most controversial health policies, would have needed every Republican vote on the Senate health committee to advance her nomination to the Senate floor. It became clear on Tuesday night that she did not have enough votes.
The decision to withdraw her nomination was first reported by Axios.
The panel’s chairman, Senator Bill Cassidy, Republican of Louisiana, had expressed reservations about Dr. Overton from the start, saying her role in an executive order this summer that called for reducing the number of vaccines recommended for children was “almost disqualifying.” During her confirmation hearing in September, Mr. Cassidy, a physician, had pressed her repeatedly on whether she would stand up to President Trump on vaccines, particularly the measles vaccine. Dr. Overton said: “It is safe and effective and it is our best tool right now in the public health response to the measles outbreak.”
As lawmakers broached other topics, though, Dr. Overton made it clear during the hearing that she would be loyal to the president, defending his forays into decisions typically made by career scientists. “The president’s interest is in the best outcomes for the American people,” she said.
Abortion was also an issue for lawmakers of both parties. Democrats were alarmed by Dr. Overton’s past statements on the abortion pill mifepristone, which she previously called “dangerous to women.” During her confirmation hearing, Dr. Overton said that “the drug is safe and effective as labeled today” under F.D.A. regulations.
Republican were concerned that in the hearing she gave only vague answers on how she would handle a safety review of mifepristone that is underway at the agency.
The F.D.A. regulates products that account of about 20 percent of spending in the United States, including over-the-counter and prescription medications, most food, dietary supplements, cosmetics and medical devices.
It is unclear if the White House will choose another nominee as the window to confirm an F.D.A. commissioner with a Republican-led Senate is narrowing. The odds of getting a nominee confirmed once the Democrats take control of the Senate in January could be slim.
Before joining the White House during the second Trump Administration, Dr. Overton was a chief policy officer at the America First Policy Institute, a conservative think tank. She has written articles that denounced abortion as “corrosive” to women and called for more controls over prescribing abortion pills.
When Mr. Trump announced in a social media post in August that Dr. Overton would be nominated, he said he needed her at the F.D.A. to secure the nation’s role as “the WORLD LEADER for Scientific Discovery and CURES.” He also said he expected her to deliver on his priorities, including clinical trial reforms and lower drug prices.
Jonathan Swan contributed reporting.
The post White House Withdraws Nomination of Heidi Overton to Be F.D.A. Commissioner appeared first on New York Times.




